uPA-targeted oncolytic Sendai virus therapy expressing interferon-beta (ID Pharma/Kyushu University)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameuPA-targeted oncolytic Sendai virus therapy expressing interferon-beta (ID Pharma/Kyushu University)
Drug Alias NameBioKnife-IFNbeta
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionUrokinase plasminogen activator modulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptorUrokinase plasminogen activator
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesID Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesID Pharma Co LtdKyushu University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A